Based on the observations above drawn from the ZIKV map, we hypothesize that FLT3 or BRAF are the effective targets of Sorafenib in ZIKV infection, rather than VEGFR and PDGFR. This evidence concerns the gene BRAF and Zika virus infectious disease.